83 related articles for article (PubMed ID: 19745651)
21. Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania.
Nasrallah HA; Brecher M; Paulsson B
Bipolar Disord; 2006 Oct; 8(5 Pt 1):467-74. PubMed ID: 17042884
[TBL] [Abstract][Full Text] [Related]
22. Comparative efficacy of once daily, 5-day short-course therapy with clarithromycin extended-release versus twice daily, 7-day therapy with clarithromycin immediate-release in acute bacterial exacerbation of chronic bronchitis.
Gotfried M; Notario G; Spiller J; Palmer R; Busman T
Curr Med Res Opin; 2005 Feb; 21(2):245-54. PubMed ID: 15801995
[TBL] [Abstract][Full Text] [Related]
23. Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy.
Lunde JL; Nelson RE; Storandt HF
Pharmacotherapy; 2007 Aug; 27(8):1202-5. PubMed ID: 17655519
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
25. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
Dutta S; Reed RC; O'Dea RF
Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
[TBL] [Abstract][Full Text] [Related]
26. Single-dose extended-release oral azithromycin vs. 3-day azithromycin for the treatment of group A beta-haemolytic streptococcal pharyngitis/tonsillitis in adults and adolescents: a double-blind, double-dummy study.
Jorgensen DM
Clin Microbiol Infect; 2009 Dec; 15(12):1103-10. PubMed ID: 19929975
[TBL] [Abstract][Full Text] [Related]
27. A pharmacokinetic and clinical evaluation of switching patients with bipolar I disorder from delayed-release to extended-release divalproex.
Davis LL; Li X; Bartolucci AA; Williford RB; Lowe JS
J Clin Psychiatry; 2007 Oct; 68(10):1546-51. PubMed ID: 17960970
[TBL] [Abstract][Full Text] [Related]
28. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
Dutta S; Reed RC; Cavanaugh JH
J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension.
Fagan TC; Haggert BE; Liss C
Clin Ther; 1994; 16(4):634-46. PubMed ID: 7982251
[TBL] [Abstract][Full Text] [Related]
30. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
Dulac O; Alvarez JC
Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
[TBL] [Abstract][Full Text] [Related]
31. Cost analysis of divalproex sodium extended-release compared to valproic acid in the treatment of bipolar disorder.
Schumock GT; Walton SM; Gupta SR; Cramer JA
Curr Med Res Opin; 2007 Aug; 23(8):1997-2004. PubMed ID: 17637202
[TBL] [Abstract][Full Text] [Related]
32. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
Dutta S; Reed RC
Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
[TBL] [Abstract][Full Text] [Related]
33. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
34. Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms.
McIntyre RS; Konarski JZ; Jones M; Paulsson B
J Affect Disord; 2007; 100 Suppl 1():S5-14. PubMed ID: 17391773
[TBL] [Abstract][Full Text] [Related]
35. Divalproex sodium extended-release for the prophylaxis of migraine headache in adolescents: results of a stand-alone, long-term open-label safety study.
Apostol G; Lewis DW; Laforet GA; Robieson WZ; Fugate JM; Abi-Saab WM; Saltarelli MD
Headache; 2009 Jan; 49(1):45-53. PubMed ID: 19040679
[TBL] [Abstract][Full Text] [Related]
36. [Valproate sustained release in the treatment of epilepsy].
Stefan H; Fraunberger B
Fortschr Neurol Psychiatr; 2005 Nov; 73(11):681-6. PubMed ID: 16283612
[TBL] [Abstract][Full Text] [Related]
37. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania.
McElroy SL; Keck PE; Stanton SP; Tugrul KC; Bennett JA; Strakowski SM
J Clin Psychiatry; 1996 Apr; 57(4):142-6. PubMed ID: 8601548
[TBL] [Abstract][Full Text] [Related]
38. Safety and tolerability of divalproex sodium extended-release in the prophylaxis of migraine headaches: results of an open-label extension trial in adolescents.
Apostol G; Pakalnis A; Laforet GA; Robieson WZ; Olson E; Abi-Saab WM; Saltarelli M
Headache; 2009 Jan; 49(1):36-44. PubMed ID: 19040678
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of switching psychiatric patients from a delayed-release to an extended-release formulation of divalproex sodium.
Horne RL; Cunanan C
J Clin Psychopharmacol; 2003 Apr; 23(2):176-81. PubMed ID: 12640219
[TBL] [Abstract][Full Text] [Related]
40. Divalproex utility in bipolar disorder with co-occurring cocaine dependence: a pilot study.
Salloum IM; Douaihy A; Cornelius JR; Kirisci L; Kelly TM; Hayes J
Addict Behav; 2007 Feb; 32(2):410-5. PubMed ID: 16814474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
